All News
ASDAS Activity Correlates with Xray Progression in Spondyloarthritis
Investigators analyzed a prospective study of patients with early axial spondyloarthritis (axSpA) to assess predictors of outcome.
Read Article
Ustekinumab Effective and Safe in Crohn's Colitis
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Read Article
Three Year Data on Secukinumab
Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC.
Read Article
My ACR 2016 Highlights
Washington is always a great city to visit (even though there were a few protesters floating around the streets). I hope the posts I made were of interest to some readers. Here are my top 5 highlights from ACR 2016:
Read Article
ACR16 Day 4 Ends with Rheumatology Roundup
The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.
Read Article
Dual Cytokine Inhibition for RA
The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.
Read Article
Guselkumab Efficacy and Tolerability in PsA/PsO
New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.
Read Article
CORRONA Presentations at ACR 2016
CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.
Read Article
SPIRIT P1 Study - Ixekinumab Sustains Efficacy at 52 Weeks in Psoriatic Arthritis
Ixekinumab (IXE) is an IGG4 monoclonal antibody bindings with high affinity to IL -17A. Currently marketed at Taltz and approved for use in chronic plaque psoriasis, the agent is also being developed for use in psoriatic arthritis.
Read Article
Unmet Needs: Prediction and early detection in SpA first-degree relatives
Why do diseases manifest in some family members but not in others? Antibodies can be found in patients who do not meet criteria for treatment, especially in first-degree relatives.
Read Article
RheumNow Week in Review – 11 November 2016
Dr Cush reviews highlights from this week on RheumNow.com
Read Article
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
Janssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read Article
Enbrel Approved for Pediatric Chronic Plaque Psoriasis
Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis. Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.
Read Article
When Cheap Generics Morph Into Expensive Prescriptions
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
Read Article
Prevalence of Inflammatory Bowel Disease Increases
The MMWR has reported that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), previously (1999) had an estimated 1.8 million (0.9%) prevalence. But as of 2015, an estimated 3.1 million (1.3%) of U.S.
Read Article
The RheumNow Week in Review – 28 October 2016
Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
Read Article
POSTURE Study: Apremilast Fails in Ankylosing Spondylitis
ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.
Read Article
